Commonly targeted antigens in PCa vaccine development include prostatic acid phosphatase (PAP), prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), and six-transmembrane epithelial antigen of the prostate-1 (STEAP1), due to their overexpression and enrichment in tumors compared with the normal prostate. This evidence concerns the gene ACP3 and posterior cortical atrophy.